GSE185519 1 V 7 GILTERITINIB HUMAN DN (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE185519 1 V 7 GILTERITINIB HUMAN DN.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE185519 1 V 7 GILTERITINIB HUMAN DN.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE185519 1 V 7 GILTERITINIB HUMAN DN.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE185519 1 V 7 GILTERITINIB HUMAN DN.

Results found

Linked to

 

Label

Description

 

Gene

NFIL3 like basic leucine zipper

Gene

GET1-SH3BGR readthrough

Gene

solute carrier family 25 member 25

Gene

gamma-glutamyltransferase 5

Gene

solute carrier family 6 member 9

Gene

tRNA splicing endonuclease subunit 15

Gene

CECR2 histone acetyl-lysine reader

Gene

cystathionine beta-synthase like

Gene

NFKB inhibitor delta

Gene

amyloid beta precursor protein binding family B member 1

  • Gene

    NFIL3 like basic leucine zipper


  • Gene

    GET1-SH3BGR readthrough


  • Gene

    solute carrier family 25 member 25


  • Gene

    gamma-glutamyltransferase 5


  • Gene

    solute carrier family 6 member 9


  • Gene

    tRNA splicing endonuclease subunit 15


  • Gene

    CECR2 histone acetyl-lysine reader


  • Gene

    cystathionine beta-synthase like


  • Gene

    NFKB inhibitor delta


  • Gene

    amyloid beta precursor protein binding family B member 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.